ESMO Highlights 2022 in Gynecological Cancer: Are we curing ovarian cancer patients?
This year`s congress provided overall survival (OS) results from the SOLO-1/GOG 3004 and PAOLA-1/ENGOT-ov25 trials investigating olaparib (ola) alone and in combination with bevacizumab (bev) as maintenance therapy in patients with advanced ovarian cancer (AOC). Based on the results of randomized phase 3 trials, Poly(adenosine diphosphate-ribose) pol-ymerase inhibitors (PARPi) have been approved as a new standard of care in AOC and have revolutionized the way patients are treated in the front-line (1–4) and recurrent setting (5–7). Currently, ola, niraparib, ola plus bev and bev demonstrated significant improvements in progression-free survival (PFS) and are approved for first-line maintenance therapy (1, 3, 4, 8)
Bitte loggen Sie sich ein um den Inhalt zu sehen